Working… Menu

Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis (BEST-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01981161
Recruitment Status : Completed
First Posted : November 11, 2013
Last Update Posted : August 25, 2020
European Commission
Information provided by (Responsible Party):
University Hospital, Toulouse

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 20, 2018
Actual Study Completion Date : November 30, 2018